How to manage folliculitis in a patient taking Rinvoq (upadacitinib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Folliculitis Due to Rinvoq (Upadacitinib)

Immediate Assessment and Treatment Approach

For folliculitis developing in patients on Rinvoq, initiate topical clindamycin 1% solution or gel twice daily for at least 12 weeks as first-line therapy while continuing Rinvoq, and escalate to oral tetracycline 500 mg twice daily for 4-12 weeks if the folliculitis is moderate to severe or fails to respond to topical treatment. 1, 2

Severity-Based Treatment Algorithm

Mild Folliculitis (Grade 1):

  • Continue Rinvoq at current dose 3
  • Apply topical clindamycin 1% solution/gel twice daily for 12 weeks 1
  • If signs of superadded infection develop, add alcohol-free topical antibiotics for at least 14 days 3
  • Alternative topical options include erythromycin 1% cream or metronidazole 0.75% 2

Moderate Folliculitis (Grade 2):

  • Continue Rinvoq at current dose as most cases improve within 2 weeks 3
  • Escalate to oral tetracycline 500 mg twice daily for 4-12 weeks 1, 2
  • Doxycycline and minocycline are more effective than tetracycline, though neither is superior to the other 1, 2
  • Consider dose reduction or temporary interruption of Rinvoq only if folliculitis is prolonged or intolerable 3
  • Add short-term topical corticosteroids (hydrocortisone 1-2.5% or eumovate ointment to face; betnovate, elocon, or dermovate ointment to body) for 2-3 weeks 3
  • Combine systemic antibiotics with topical therapy to minimize bacterial resistance 1

Severe Folliculitis (Grade 3):

  • Temporarily interrupt Rinvoq per FDA labeling guidance 4
  • Initiate oral tetracycline 500 mg twice daily 1, 2
  • Obtain bacterial cultures to guide antibiotic selection 2, 5
  • For suspected MRSA, consider trimethoprim-sulfamethoxazole, doxycycline, or clindamycin 2
  • Resume Rinvoq only once infection is controlled 4

Essential Preventive Measures

Skin Care Protocol:

  • Cleanse with gentle pH-neutral soaps and tepid water 3, 1
  • Pat skin dry after showering—avoid rubbing 3, 1
  • Wear loose-fitting cotton clothing instead of synthetic materials 3, 1
  • Apply hypoallergenic moisturizing emollients once daily, but avoid greasy creams in affected areas as they facilitate folliculitis development 3, 1
  • Use shampoos that reduce scalp folliculitis risk such as ketoconazole, betadine, or ceanel 3

Critical Pitfalls to Avoid:

  • Do not use topical acne medications without dermatologist supervision, as they may irritate and worsen the condition 3, 1
  • Avoid prolonged topical steroid use, which can cause skin atrophy and paradoxically worsen folliculitis 3, 1
  • Do not manipulate or pick at affected skin, as this increases infection risk 3, 5

Management of Recurrent or Refractory Cases

For Recurrent Folliculitis:

  • Implement a 5-day decolonization regimen with intranasal mupirocin twice daily, daily chlorhexidine body washes, and decontamination of personal items 1, 2, 5
  • Culture recurrent lesions and treat with a 5-10 day course of an antibiotic active against the isolated pathogen 1, 5
  • Consider oral clindamycin 150 mg once daily for 3 months, which decreases subsequent infections by approximately 80% 2

For Refractory Cases:

  • If no improvement after 8-12 weeks of oral tetracycline, consider combination therapy with oral clindamycin 300 mg twice daily plus rifampicin 600 mg once daily for 10 weeks 2
  • For localized lesions at risk of scarring, intralesional corticosteroids can provide rapid improvement 1, 2
  • Consult dermatology for chronic grade 2 or higher folliculitis, as it can significantly impact quality of life 3

Special Considerations for Rinvoq

FDA Safety Warnings:

  • Rinvoq increases risk of serious infections including cellulitis 4
  • Monitor closely for signs of infection during treatment 4
  • If herpes zoster develops (which appears more common in patients on JAK inhibitors in Japan), consider temporarily interrupting Rinvoq until the episode resolves 4
  • Obtain bacterial swabs if secondary infection is suspected, as Staphylococcus aureus is the most frequently detected infectious agent 3, 5

Surgical Intervention:

  • For large furuncles or abscesses, incision and drainage is the primary and most effective treatment 2, 5
  • Perform thorough evacuation of pus and probe the cavity to break up loculations 2
  • Obtain Gram stain and culture of purulent material to guide subsequent therapy 2, 5

Treatment Duration and Monitoring

  • Initial systemic antibiotic duration is 5 days, with extension if no improvement occurs 1, 2
  • Limit systemic antibiotic use to the shortest possible duration with re-evaluation at 3-4 months to minimize bacterial resistance 1, 2
  • Reassess after 2 weeks or at any worsening of symptoms 2

Alternative Populations

  • For pregnant women or children under 8 years who cannot take tetracyclines, use erythromycin or azithromycin instead 1, 2

References

Guideline

First-Line Treatment for Folliculitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Chronic Folliculitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Folliculitis in the Groin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.